Overview
Aliquot reports the existence and evidence type of reviewed human research without turning study findings into a benefit claim or personal recommendation.
A clinical-trial listing establishes research activity, not approval, effectiveness, safety for personal use, or an appropriate regimen.
Human pharmacokinetic context
7.5 days
Peer-reviewed human study · subcutaneous injection
Half-life is descriptive population context, not a dosing interval, a prediction of an individual's response, or a recommendation. Route-mismatched and uncited estimates are withheld.
Limitations
- Investigational research is not evidence of FDA approval.
- Study estimates do not predict an individual's response.
Related calculation tools
Aliquot's browser-only tools transform values you already have. They do not select a compound, suggest an amount, provide presets, or store your entries.
Sources
- Cagrilintide phase 3 weight-management study Current phase 3 research status.
- Safety, tolerability, pharmacokinetics, and pharmacodynamics of cagrilintide with semaglutide Route-specific human pharmacokinetic context.
- Aliquot compound library methodology Editorial scope and withholding rules.